Abstract 380P
Background
MRI imaging is an essential tool in diagnosing glioblastoma and it can give various anatomical details related to disease. It gives an assessment of involvement of disease with ventricular – subventricular zone (VSVZ), subgranular (SGZ) and corpus callosum (CC). This study aims at assessment of survival outcomes in diseases involving neurogenic zones and corpus callosum and the associated prognostic factors.
Methods
We retrospectively analyzed 376 adult patients treated for histologically proven Glioblastoma. MRI studies were assessed for the tumor volume and its association with the neurogenic zones and corpus callosum. Age of patient, comorbidities associated, performance status, extent of resection and radiation doses received by these structures were evaluated. Overall (OS) and progression free (PFS) survivals were calculated and analyzed with multivariate Cox analyses.
Results
Of the 376 patients, 121 had VSVZ involved, 62 had CC involved and 43 had SGZ involved and remaining 150 had cortical involvement and the latter served as controls. Overall median age was 60.4 years, median Karnofsky performance score (KPS) was 80 and median tumor volume was 34.7 cm3. Gross total resection (GTR) was seen in 50.6% and subtotal resection in 38.1% and rest were unresectable. On multivariate cox analyses, VSVZ was found to be an independent factor for poor OS and PFS. Besides, increasing age, lower KPS, less than GTR status were associated independent factors for reduced survival.
Conclusions
Patients with GBMs contacting the VSVZ and SGZ neurogenic zones exhibit divergent clinical patterns of tumor recurrence and survival and VSVZ involvement are associated with early recurrences and lower survival. VSVZ has a rich stem cell and growth factor microenvironment and these structures can be considered as organs at risk in uninvolved disease for probably better outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract